{
  "page_id": 1,
  "metadata": {
    "file_name": "doc_0741.png",
    "image_width": 754,
    "image_height": 1000
  },
  "lines": [
    {
      "text": "Lung Cancer and the Debrisoquine Metabolic",
      "bbox": [
        57,
        102,
        502,
        130
      ],
      "confidence": 0.9968201518058777
    },
    {
      "text": "Phenotype",
      "bbox": [
        57,
        131,
        164,
        165
      ],
      "confidence": 0.9999455213546753
    },
    {
      "text": "Neil E. Caporaso,* Margaret A. Tucker, Robert N. Hoover, Richard B.",
      "bbox": [
        59,
        176,
        554,
        205
      ],
      "confidence": 0.979610025882721
    },
    {
      "text": "Hayes, Linda W. Pickle, Haleem J. Issag, Gary M. Muschik, Laureen",
      "bbox": [
        60,
        196,
        542,
        223
      ],
      "confidence": 0.9860761165618896
    },
    {
      "text": "Green-Gallo, Daina Buivys, Seena Aisner, James H. Resau, Benjamin F.",
      "bbox": [
        60,
        214,
        562,
        241
      ],
      "confidence": 0.9817981719970703
    },
    {
      "text": "Trump, David Tollerud, Ainsley Weston, Curtis C. Harris",
      "bbox": [
        60,
        234,
        455,
        259
      ],
      "confidence": 0.9777892827987671
    },
    {
      "text": "olizer phenotype were a higher risk of developing bronchial",
      "bbox": [
        387,
        277,
        716,
        295
      ],
      "confidence": 0.9905301332473755
    },
    {
      "text": "carcinoma than were intermediate and poor metabolizers of the",
      "bbox": [
        387,
        291,
        716,
        311
      ],
      "confidence": 0.9884465336799622
    },
    {
      "text": "In a case-control study, we tested the hypothesis that the",
      "bbox": [
        60,
        297,
        377,
        320
      ],
      "confidence": 0.95924311876297
    },
    {
      "text": "drug. One concerm in interpreting these data was the use of",
      "bbox": [
        387,
        306,
        717,
        326
      ],
      "confidence": 0.9526618719100952
    },
    {
      "text": "genetically determined ability to metabolize debrisoquine is",
      "bbox": [
        61,
        313,
        376,
        334
      ],
      "confidence": 0.99323570728302
    },
    {
      "text": "subjects with chronic obstructive pulmonary disease as a soie",
      "bbox": [
        386,
        321,
        716,
        341
      ],
      "confidence": 0.9715586304664612
    },
    {
      "text": "related to risk of lung cancer. Overall, individuals who were",
      "bbox": [
        61,
        329,
        376,
        348
      ],
      "confidence": 0.981387734413147
    },
    {
      "text": "comparison group. Other studies considering this association",
      "bbox": [
        387,
        336,
        716,
        355
      ],
      "confidence": 0.989630401134491
    },
    {
      "text": "extensive metabolizers of debrisoquine were at significantly",
      "bbox": [
        62,
        345,
        375,
        361
      ],
      "confidence": 0.991557240486145
    },
    {
      "text": "greater risk of lung cancer than those who were poor or",
      "bbox": [
        61,
        358,
        376,
        378
      ],
      "confidence": 0.9804179668426514
    },
    {
      "text": "cism of the epidemiologic methods (20:2/).",
      "bbox": [
        387,
        366,
        610,
        384
      ],
      "confidence": 0.9780687689781189
    },
    {
      "text": "have produced conflicting results (/8, 19) or have attracted criti-",
      "bbox": [
        389,
        354,
        715,
        368
      ],
      "confidence": 0.9713797569274902
    },
    {
      "text": "intermediate metabolizers (odds ratio = 6.1; 95% confidence",
      "bbox": [
        60,
        373,
        376,
        392
      ],
      "confidence": 0.9860849976539612
    },
    {
      "text": "To examine the hypothesis of an association. of risk of lung",
      "bbox": [
        400,
        382,
        715,
        397
      ],
      "confidence": 0.9837964773178101
    },
    {
      "text": "interval = 2.2-17.1). In this study, case patients had lung",
      "bbox": [
        60,
        388,
        377,
        406
      ],
      "confidence": 0.9934912919998169
    },
    {
      "text": "cancer, and control subjects had either chronic obstructive",
      "bbox": [
        61,
        402,
        377,
        421
      ],
      "confidence": 0.9765627980232239
    },
    {
      "text": "a formal epidemiologic case-control study. We used two separate",
      "bbox": [
        387,
        410,
        716,
        428
      ],
      "confidence": 0.9772934317588806
    },
    {
      "text": "cancer with the ability to metabolize debrisoquine, we conducted",
      "bbox": [
        389,
        398,
        715,
        412
      ],
      "confidence": 0.9815906286239624
    },
    {
      "text": "pulmonary disease or cancers other than lung cancer. Results",
      "bbox": [
        61,
        416,
        377,
        438
      ],
      "confidence": 0.9877691268920898
    },
    {
      "text": "comparison groups and adjusted results for recognized risk",
      "bbox": [
        387,
        425,
        716,
        444
      ],
      "confidence": 0.991097629070282
    },
    {
      "text": "were adjusted for age, race, asbestos exposure, and smoking.",
      "bbox": [
        61,
        431,
        376,
        452
      ],
      "confidence": 0.991527795791626
    },
    {
      "text": "Both black and white individuals who were extensive metab-",
      "bbox": [
        61,
        445,
        377,
        467
      ],
      "confidence": 0.9929736852645874
    },
    {
      "text": "genetically determined differences in the ability to melabolize:",
      "bbox": [
        388,
        454,
        717,
        474
      ],
      "confidence": 0.9801138639450073
    },
    {
      "text": "factors for lung cancer. This work focuses on the assessment of",
      "bbox": [
        389,
        443,
        716,
        457
      ],
      "confidence": 0.9871175289154053
    },
    {
      "text": "olizers of debrisoquine were at significantly increased risk",
      "bbox": [
        61,
        461,
        377,
        482
      ],
      "confidence": 0.9912394285202026
    },
    {
      "text": "after similar adjustment (for blacks, odds ratio = 4.5, 95%",
      "bbox": [
        62,
        476,
        375,
        495
      ],
      "confidence": 0.9711047410964966
    },
    {
      "text": "of lung cancer susceptibility.",
      "bbox": [
        389,
        486,
        532,
        501
      ],
      "confidence": 0.9965723752975464
    },
    {
      "text": "debrisoquine as an approach to elucidating a genetic component",
      "bbox": [
        390,
        473,
        716,
        487
      ],
      "confidence": 0.9812905192375183
    },
    {
      "text": "confidence interval = 1.1-18.1; for whites, odds ratio = 10.2,",
      "bbox": [
        62,
        490,
        376,
        511
      ],
      "confidence": 0.9828274846076965
    },
    {
      "text": "95% confidence interval = 2.0-51.4). Significantly increased",
      "bbox": [
        60,
        505,
        377,
        525
      ],
      "confidence": 0.9930198788642883
    },
    {
      "text": "risk of lung cancer was also present for individuals who were",
      "bbox": [
        61,
        519,
        378,
        540
      ],
      "confidence": 0.9903709292411804
    },
    {
      "text": "Subjects and Methods",
      "bbox": [
        388,
        519,
        533,
        537
      ],
      "confidence": 0.9994810819625854
    },
    {
      "text": "extensive metabolizers when subjects with chronic obstruc-",
      "bbox": [
        61,
        534,
        377,
        553
      ],
      "confidence": 0.9803664088249207
    },
    {
      "text": "tive pulmonary disease or other cancers were considered",
      "bbox": [
        61,
        547,
        376,
        569
      ],
      "confidence": 0.9918372631072998
    },
    {
      "text": "Subjects",
      "bbox": [
        388,
        542,
        437,
        560
      ],
      "confidence": 0.9492416977882385
    },
    {
      "text": "separately. These data confirm that the ability to metabolize",
      "bbox": [
        61,
        562,
        377,
        583
      ],
      "confidence": 0.9934344291687012
    },
    {
      "text": "Patients with histologically confirmed lung cancer who had not",
      "bbox": [
        401,
        566,
        715,
        581
      ],
      "confidence": 0.9977706074714661
    },
    {
      "text": "debrisoquine is a major determinant of susceptibility to lung",
      "bbox": [
        61,
        580,
        376,
        595
      ],
      "confidence": 0.9925335049629211
    },
    {
      "text": "yet received radiation or chemotherapy were identified at the",
      "bbox": [
        388,
        581,
        715,
        596
      ],
      "confidence": 0.9844521284103394
    },
    {
      "text": "cancer. Evaluation of the marker in other case-control",
      "bbox": [
        60,
        593,
        377,
        611
      ],
      "confidence": 0.9965365529060364
    },
    {
      "text": "settings, further exploration of racial differences, and the",
      "bbox": [
        60,
        607,
        377,
        626
      ],
      "confidence": 0.9939039349555969
    },
    {
      "text": "University of Maryland Hospital and the Baltimore: Veterans",
      "bbox": [
        390,
        596,
        716,
        610
      ],
      "confidence": 0.9865822196006775
    },
    {
      "text": "prospective evaluation of this marker in subgroups at high",
      "bbox": [
        60,
        622,
        376,
        642
      ],
      "confidence": 0.9876083731651306
    },
    {
      "text": "risk of lung cancer are areas worthy of further study. [J Nati",
      "bbox": [
        60,
        637,
        376,
        656
      ],
      "confidence": 0.9831178784370422
    },
    {
      "text": "Cancer Inst 82:1264-1272, 1990]",
      "bbox": [
        60,
        653,
        236,
        671
      ],
      "confidence": 0.9685245752334595
    },
    {
      "text": "Received May 4, 1990; accepted May 9, 1990.",
      "bbox": [
        398,
        653,
        593,
        668
      ],
      "confidence": 0.9567647576332092
    },
    {
      "text": "N. E. Caporaso, M. A. Tucker, R. N. Hoover. R. B. Hayes (Environmental",
      "bbox": [
        399,
        667,
        718,
        681
      ],
      "confidence": 0.9602184891700745
    },
    {
      "text": "Epidemioiogy Branch). A. Weson, C. C. Harris (Laboratory of Human Carcino-",
      "bbox": [
        390,
        679,
        718,
        694
      ],
      "confidence": 0.9637914896011353
    },
    {
      "text": "While exposure to tobacco smoke is widely accepted as the",
      "bbox": [
        73,
        689,
        376,
        710
      ],
      "confidence": 0.9722718596458435
    },
    {
      "text": "penesis, Division of Cancer Exiology). National Cancer Institute. Bethesda, Md.",
      "bbox": [
        389,
        692,
        718,
        707
      ],
      "confidence": 0.9825022220611572
    },
    {
      "text": "major etiologic factor in lung cancer, differences in individual",
      "bbox": [
        60,
        705,
        377,
        725
      ],
      "confidence": 0.9703943729400635
    },
    {
      "text": "L. W. Picklc. Vincen: T. Lombardi Cancer Rescarch Cenier, Georgetown",
      "bbox": [
        398,
        703,
        720,
        720
      ],
      "confidence": 0.9596704840660095
    },
    {
      "text": "susceptibility have been inferred from the observation that only a",
      "bbox": [
        59,
        720,
        377,
        740
      ],
      "confidence": 0.9807693958282471
    },
    {
      "text": "University, Washington, DC:",
      "bbox": [
        389,
        716,
        513,
        729
      ],
      "confidence": 0.9757319688796997
    },
    {
      "text": "minority of cigarette smokers have diagnoses of lung cancer",
      "bbox": [
        58,
        735,
        377,
        755
      ],
      "confidence": 0.9815115928649902
    },
    {
      "text": "Frederick Cancer Rescarch Center, National Cancer Institutc. Frederick, Md..",
      "bbox": [
        388,
        741,
        711,
        756
      ],
      "confidence": 0.9569957256317139
    },
    {
      "text": "H. J. Issag, G. M. Muschik, Laboratory of Chemical Synthesis and Analysis.",
      "bbox": [
        398,
        728,
        719,
        744
      ],
      "confidence": 0.9671466946601868
    },
    {
      "text": "(7.2). Variation in the ability to metabolize xenobiotics has been",
      "bbox": [
        59,
        751,
        376,
        768
      ],
      "confidence": 0.9634991884231567
    },
    {
      "text": "L. Green-Gallo. D. Buivys. S. Aisner. J. H. Resau. B: F. Trump. University of",
      "bbox": [
        398,
        753,
        719,
        769
      ],
      "confidence": 0.9561752676963806
    },
    {
      "text": "considered as a possible explanation for this phenomenon (3), and",
      "bbox": [
        58,
        766,
        376,
        783
      ],
      "confidence": 0.9771067500114441
    },
    {
      "text": "Maryland School of Medicine. Department of Pathoiogy. and Veterans Adrun-",
      "bbox": [
        388,
        766,
        718,
        781
      ],
      "confidence": 0.9592944383621216
    },
    {
      "text": "this hypothesis is consistent with family and twin studies (4-6), as",
      "bbox": [
        57,
        779,
        377,
        799
      ],
      "confidence": 0.9721771478652954
    },
    {
      "text": "istration Medical Center, Balimore, Md.",
      "bbox": [
        389,
        779,
        558,
        792
      ],
      "confidence": 0.9513320922851562
    },
    {
      "text": "well as cytogenetic and molecular investigations (7-12) that have",
      "bbox": [
        56,
        794,
        377,
        814
      ],
      "confidence": 0.9726907014846802
    },
    {
      "text": "D. Tollerud, University of Ptsburgh. Graduate School of Public Health,",
      "bbox": [
        398,
        790,
        718,
        806
      ],
      "confidence": 0.9437111020088196
    },
    {
      "text": "indicated a role for genetic predisposition in lung cancer etiology",
      "bbox": [
        55,
        809,
        375,
        830
      ],
      "confidence": 0.9766663312911987
    },
    {
      "text": "Pittsburgh, Pa.",
      "bbox": [
        389,
        805,
        451,
        817
      ],
      "confidence": 0.9209831953048706
    },
    {
      "text": "We thank Steve Fox for technical assistance., leff Idie for 7-methoxy-guanoxan",
      "bbox": [
        398,
        815,
        719,
        832
      ],
      "confidence": 0.9550202488899231
    },
    {
      "text": "The metabolism of the antihypertensive drug debrisoquine is",
      "bbox": [
        68,
        824,
        376,
        844
      ],
      "confidence": 0.9940338730812073
    },
    {
      "text": "insemal suandard, Karen Fisher for bier efforts as first-study nursc, Jack Cahill.",
      "bbox": [
        388,
        829,
        719,
        844
      ],
      "confidence": 0.9555755257606506
    },
    {
      "text": "under autosomal genetic control (/3-15). and inheritance of the",
      "bbox": [
        53,
        839,
        376,
        860
      ],
      "confidence": 0.9781982898712158
    },
    {
      "text": "Sherri Sanboume: Patricia Lancey, and Marci Bresiow for their services through-",
      "bbox": [
        388,
        842,
        718,
        857
      ],
      "confidence": 0.9759435653686523
    },
    {
      "text": "trait conferring ability to \"extensively\" metabolize the drug has",
      "bbox": [
        53,
        854,
        376,
        875
      ],
      "confidence": 0.9751377105712891
    },
    {
      "text": "out the study. Anell Bond and Robin Micliniyre for: assastung in compules.",
      "bbox": [
        387,
        854,
        720,
        870
      ],
      "confidence": 0.9430810213088989
    },
    {
      "text": "been suggested as a host susceptibility factor for lung cancer",
      "bbox": [
        52,
        868,
        376,
        891
      ],
      "confidence": 0.9788898825645447
    },
    {
      "text": "programming. and Drs. Slawson. Didolka, Elias. Rubsn. and Albin for their",
      "bbox": [
        388,
        869,
        720,
        882
      ],
      "confidence": 0.9441030621528625
    },
    {
      "text": "(/6.17): In an carlier study comparing patients with lung cancer",
      "bbox": [
        51,
        883,
        376,
        907
      ],
      "confidence": 0.9857927560806274
    },
    {
      "text": "invaluable clinical assistance:",
      "bbox": [
        387,
        879,
        513,
        894
      ],
      "confidence": 0.9445062279701233
    },
    {
      "text": "*Correspondence to: Neil E. Caporaso. M.D.. Environmenal Epidemaology",
      "bbox": [
        398,
        892,
        720,
        908
      ],
      "confidence": 0.950958251953125
    },
    {
      "text": "and patients with chronic obstructive pulmonary disease, white.",
      "bbox": [
        49,
        897,
        376,
        925
      ],
      "confidence": 0.9647543430328369
    },
    {
      "text": "Branch. Executive Plaza North. Rm. 439. National Insastues of Health, Bethesda.",
      "bbox": [
        387,
        904,
        720,
        920
      ],
      "confidence": 0.9334511160850525
    },
    {
      "text": "British cigarette smokers with the extensive debrisoquine-metab-",
      "bbox": [
        50,
        913,
        374,
        939
      ],
      "confidence": 0.9920320510864258
    },
    {
      "text": "MD 20892.",
      "bbox": [
        387,
        915,
        438,
        932
      ],
      "confidence": 0.9102111458778381
    },
    {
      "text": ".264",
      "bbox": [
        5,
        951,
        45,
        975
      ],
      "confidence": 0.993859052658081
    },
    {
      "text": "Journal of thc National Cancer Institute",
      "bbox": [
        530,
        943,
        720,
        960
      ],
      "confidence": 0.9522398710250854
    },
    {
      "text": "2029288599",
      "bbox": [
        533,
        973,
        677,
        993
      ],
      "confidence": 0.9997161626815796
    }
  ],
  "full_text": "Lung Cancer and the Debrisoquine Metabolic\nPhenotype\nNeil E. Caporaso,* Margaret A. Tucker, Robert N. Hoover, Richard B.\nHayes, Linda W. Pickle, Haleem J. Issag, Gary M. Muschik, Laureen\nGreen-Gallo, Daina Buivys, Seena Aisner, James H. Resau, Benjamin F.\nTrump, David Tollerud, Ainsley Weston, Curtis C. Harris\nolizer phenotype were a higher risk of developing bronchial\ncarcinoma than were intermediate and poor metabolizers of the\nIn a case-control study, we tested the hypothesis that the\ndrug. One concerm in interpreting these data was the use of\ngenetically determined ability to metabolize debrisoquine is\nsubjects with chronic obstructive pulmonary disease as a soie\nrelated to risk of lung cancer. Overall, individuals who were\ncomparison group. Other studies considering this association\nextensive metabolizers of debrisoquine were at significantly\ngreater risk of lung cancer than those who were poor or\ncism of the epidemiologic methods (20:2/).\nhave produced conflicting results (/8, 19) or have attracted criti-\nintermediate metabolizers (odds ratio = 6.1; 95% confidence\nTo examine the hypothesis of an association. of risk of lung\ninterval = 2.2-17.1). In this study, case patients had lung\ncancer, and control subjects had either chronic obstructive\na formal epidemiologic case-control study. We used two separate\ncancer with the ability to metabolize debrisoquine, we conducted\npulmonary disease or cancers other than lung cancer. Results\ncomparison groups and adjusted results for recognized risk\nwere adjusted for age, race, asbestos exposure, and smoking.\nBoth black and white individuals who were extensive metab-\ngenetically determined differences in the ability to melabolize:\nfactors for lung cancer. This work focuses on the assessment of\nolizers of debrisoquine were at significantly increased risk\nafter similar adjustment (for blacks, odds ratio = 4.5, 95%\nof lung cancer susceptibility.\ndebrisoquine as an approach to elucidating a genetic component\nconfidence interval = 1.1-18.1; for whites, odds ratio = 10.2,\n95% confidence interval = 2.0-51.4). Significantly increased\nrisk of lung cancer was also present for individuals who were\nSubjects and Methods\nextensive metabolizers when subjects with chronic obstruc-\ntive pulmonary disease or other cancers were considered\nSubjects\nseparately. These data confirm that the ability to metabolize\nPatients with histologically confirmed lung cancer who had not\ndebrisoquine is a major determinant of susceptibility to lung\nyet received radiation or chemotherapy were identified at the\ncancer. Evaluation of the marker in other case-control\nsettings, further exploration of racial differences, and the\nUniversity of Maryland Hospital and the Baltimore: Veterans\nprospective evaluation of this marker in subgroups at high\nrisk of lung cancer are areas worthy of further study. [J Nati\nCancer Inst 82:1264-1272, 1990]\nReceived May 4, 1990; accepted May 9, 1990.\nN. E. Caporaso, M. A. Tucker, R. N. Hoover. R. B. Hayes (Environmental\nEpidemioiogy Branch). A. Weson, C. C. Harris (Laboratory of Human Carcino-\nWhile exposure to tobacco smoke is widely accepted as the\npenesis, Division of Cancer Exiology). National Cancer Institute. Bethesda, Md.\nmajor etiologic factor in lung cancer, differences in individual\nL. W. Picklc. Vincen: T. Lombardi Cancer Rescarch Cenier, Georgetown\nsusceptibility have been inferred from the observation that only a\nUniversity, Washington, DC:\nminority of cigarette smokers have diagnoses of lung cancer\nFrederick Cancer Rescarch Center, National Cancer Institutc. Frederick, Md..\nH. J. Issag, G. M. Muschik, Laboratory of Chemical Synthesis and Analysis.\n(7.2). Variation in the ability to metabolize xenobiotics has been\nL. Green-Gallo. D. Buivys. S. Aisner. J. H. Resau. B: F. Trump. University of\nconsidered as a possible explanation for this phenomenon (3), and\nMaryland School of Medicine. Department of Pathoiogy. and Veterans Adrun-\nthis hypothesis is consistent with family and twin studies (4-6), as\nistration Medical Center, Balimore, Md.\nwell as cytogenetic and molecular investigations (7-12) that have\nD. Tollerud, University of Ptsburgh. Graduate School of Public Health,\nindicated a role for genetic predisposition in lung cancer etiology\nPittsburgh, Pa.\nWe thank Steve Fox for technical assistance., leff Idie for 7-methoxy-guanoxan\nThe metabolism of the antihypertensive drug debrisoquine is\ninsemal suandard, Karen Fisher for bier efforts as first-study nursc, Jack Cahill.\nunder autosomal genetic control (/3-15). and inheritance of the\nSherri Sanboume: Patricia Lancey, and Marci Bresiow for their services through-\ntrait conferring ability to \"extensively\" metabolize the drug has\nout the study. Anell Bond and Robin Micliniyre for: assastung in compules.\nbeen suggested as a host susceptibility factor for lung cancer\nprogramming. and Drs. Slawson. Didolka, Elias. Rubsn. and Albin for their\n(/6.17): In an carlier study comparing patients with lung cancer\ninvaluable clinical assistance:\n*Correspondence to: Neil E. Caporaso. M.D.. Environmenal Epidemaology\nand patients with chronic obstructive pulmonary disease, white.\nBranch. Executive Plaza North. Rm. 439. National Insastues of Health, Bethesda.\nBritish cigarette smokers with the extensive debrisoquine-metab-\nMD 20892.\n.264\nJournal of thc National Cancer Institute\n2029288599"
}